N/A
N=21
Lung Ultrasound in PD Patients
Peritoneal Dialysis · Hypervolemia · VEGF Overexpression
Bottom Line
View on ClinicalTrials.gov: NCT03801044 ↗Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Mar 2020
Primary outcome: Primary: Association Between Number of Kerley B Lines by Ultrasound and Serum VEGF-C Level (pg/ml) by Enzyme-linked Immunosorbent Assay — 0.29; 0.25; 0.33 ng/ml — p=0.039
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- NT-BNP, VEGF (Diagnostic_test); Echocardiography (Diagnostic_test); Chest Radiography (Radiation); Lung Ultrasound (Diagnostic_test); Bioelectrical Impedence Analysis (Diagnostic_test)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
- Primary completion
- Sep 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Association Between Number of Kerley B Lines by Ultrasound and Serum VEGF-C Level (pg/ml) by Enzyme-linked Immunosorbent Assay |
0.29; 0.25; 0.33 | 0.039 sig |
| SECONDARY Association Between Number of Kerley B Lines by Ultrasound and Dyspnea by Questionnaire |
25; 11.1 | — |
| SECONDARY Association Between Number of Kerley B Lines by Ultrasound and Class of New York Heart Association Classification |
91.7; 100 | — |
| SECONDARY Association Between Number of Kerley B Lines by Ultrasound and Presence of Third Sound/Pretibial Edema by Auscultation/Edema by Physical Examination |
0; 0 | — |
| SECONDARY Association Between Number of Kerley B Lines by Ultrasound Left Ventricle End Diastolic Diameter (mm) Obtained by the Cardiologist With Echocardiography |
4.75; 4.3 | — |
| SECONDARY Association Between Number of Kerley B Lines by Ultrasound Interventricular Septum Thickness (mm) Obtained by the Cardiologist With Echocardiography |
1.0; 1.0 | — |
| SECONDARY Association Between Number of Kerley B by Ultrasound and Posterior Wall Thickness (mm) Obtained by the Cardiologist With Echocardiography |
1.0; 0.9 | — |
| SECONDARY Association Between Number of Kerley B Lines by Ultrasound and Ejection Fraction (%) Obtained by the Cardiologist With Echocardiography |
61; 60 | — |
| SECONDARY Association Between Number of Kerley B Lines by Ultrasound and Left Ventricle End Diastolic Volume (ml) Obtained by the Cardiologist With Echocardiography |
100; 94 | — |
| SECONDARY Association Between Number of Kerley B Lines by Ultrasound and Left Atrial Volume (ml) Obtained by the Cardiologist With Echocardiography |
36; 37 | — |
| SECONDARY Association Between Number of Kerley B Lines by Ultrasound and Left Ventricle Mass Index (g/m2) Obtained by the Cardiologist With Echocardiography |
100.5; 75 | — |
| SECONDARY Association Between Number of Kerley B Lines by Ultrasound and Left Ventricle Filling Velocity (cm/Sec) Obtained by the Cardiologist With Echocardiography |
78.5; 74 | — |
| SECONDARY Association Between Number of Kerley B Lines by Ultrasound and Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity (E/E') Obtained by the Cardiologist With Echocardiography |
11.6; 10.7 | — |
| SECONDARY Association Between Number of Kerley B Lines by Ultrasound and Pulmonary Artery Systolic Pressure (mmHg) Obtained by the Cardiologist With Echocardiography |
24; 24 | — |
| SECONDARY Association Between Number of Kerley B Lines by Ultrasound and Bioimpedance Analysis [Assessed With the Body Composition Monitor; Normovolemic if Their Result Between -1,1 lt and 1,1 lt) |
0.8; 1.3 | — |
| SECONDARY Association Between Number of Kerley B Lines by Ultrasound and NT-proBNP Level (pg/ml) by Elecsys proBNP Immunoassay |
3024; 2217 | — |
Summary
Although many alternative methods are present, maintaining ideal volume status in peritoneal dialysis (PD) patients still rely on clinical evaluation due to lack of an evidence based method. Lung ultrasound (LUS) is a new method for evaluation of hidden congestion in this group. LUS findings and its relationship with other volumetric methods are investigated in this study. LUS was performed to all peritoneal dialysis patients and compared with symptoms of hypervolemia, physical examination, vascular endothelial growth factor-C (VEGF-C) and N-terminal pro-brain natriuretic peptide levels, chest radiography, echocardiography, bioelectrical impedance analysis.
Eligibility Criteria
Inclusion Criteria
- Patients older than 18 years old,
- History of PD more than 3 months,
- Providing written informed consent
Exclusion Criteria
- Patients younger than 18 years old,
- Unwilling to participate to the study,
- Immobile patients unable to perform test in the same day,
- History of PD less than 3 months,
- Presence of active infection,
- History of lung cancer and/or operations.
Data sourced from ClinicalTrials.gov (NCT03801044). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.